The IQFISH panel for lung cancer is a set of oligonucleotide-based FISH probes, premixed with IQFISH Buffer, for the detection of rearrangements involving the ALK, ROS1 and RET genes, and the detection of MET gene amplification by fluorescence in situ hybridization (FISH). These probes are to be used on lung paraffin-embedded tissue sections.
Non-Small Cell Lung Cancer (NSCLC) may involce genetic aberrations that can be used to direct therapy. For example, a fusion of ALK with EML4 occurs in about 5% of cancers and is linked to strong patient response to treatment with Crizotinib. Fusions of ROS1 and RET or amplification of MET are also observed with potentioal treatment indication. Identification of these abnormalities is often done using FISH.
This panel of IQFISH Probes combines new generations of FISH technologies-oligonucleotide-based FISH in a ready-to-use formulation of IQ Hybridization Buffer. The result is higher signal-to-noise ratios in a less than 4-hour turnaround time, reducing the costs associated with labor and assays failures.
Reduce background with probes free of repetitive DNA
Eliminate Cot-l DNA which can suppress signal
Get tighter signal co-localization for better visualization
Figure 1. Comparison of competitor ALK (left) and Agilent IQFISH ALK (right) probes. Bright, crisp, hybridization signals are produced with oligonucleotide-based probes that are designed to be free of repetitive DNA sequences and to be used without blocking agents that suppress hybridization signal.
Figure 2. IQFISH ALK inversion detection with tighter co-localization. Left: Inversion negative samples show co-localization of the orange-red and green signals. The IQFISH ALK probe (top left) shows tighter co-localized signals than the ALK probe from vendor B (bottom left). This enables easier detection of inversion events. Right: Inversion positive samples show separation of the orange-red and green signals. The relatively short separation distance (white arrow) is due to the small genomic region involved.
Hybridize probe with specimen for only 90-minutes without loss of signal
Achieve up to 25% greater operational efficiency
Figure 3. FISH smaple processing time comparison. For most laboratories, this means that FISH testing can now be done five days a week, rather than four days, improving operation efficiency by up to 25%.
Figure 4. Comparison of assay turnaround time. A 2-day savings in overall turnaround time was demonstrated in a clinical laboratory environment. The shorter hybridization step, shorter analysis time, and the less frequent need to repeat assays reduced turnaround time. (Data provided by PropPath, USCAP 2015)
Achieve more consistent results across a range of tissues
Save on reagent and labor costs by repeating assays less often
Figure 5. Comparison of LAK FISH Hybridization failures. Test failures (no hybridization signals) were compared between Agilent IQFISH and two other vendors. Sample size: Vendor A: 73 tests; Vendor B: 640 tests; Agilent IQFISH: 278 tests (Data provided by ProPath, USCAP 2015).
ALK IQFISH Break-Apart Probe
ROS1 IQFISH Break-Apart Probe
RET IQFISH Break-Apart Probe
MET IQFISH Probe with CEP7
ALK IQFISH Break-Apart Probe, 6 packs
ROS1 IQFISH Break-Apart Probe, 6 packs
RET IQFISH Break-Apart Probe, 6 packs
MET IQFISH Probe with CEP7, 6 packs
Dako Histology FISH Accessory Kit
The Instructions for Use (IFU) above are in English, French and German. For IFUs in additional languages, please click and proceed to the next page:
The product referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.
Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561–66.
Rikova K, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131:1190–203.
Takeuchi K, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. (2012) 18:378–81.
Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. (2014) 371:1963–71.
Cappuzzo F, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. (2009) 27:1667–7.
Go H, et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. (2010) 5:305–13.